Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma

Background:In a randomized phase III trial of sunitinib vs interferon-alfa (IFN-α) in metastatic renal cell carcinoma (mRCC), better baseline quality of life (QoL) was predictive of longer survival. Using this dataset, we have developed a novel prognostic tool that establishes a relationship between baseline QoL scores and median survival time.Methods… CONTINUE READING